Citigroup Downgrades Charles River to Sell, Lowers Price Target to $175
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly has downgraded Charles River Laboratories (NYSE:CRL) from Neutral to Sell and reduced the price target from $215 to $175.
October 01, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup has downgraded Charles River Laboratories from Neutral to Sell, with a reduced price target of $175, indicating potential downside.
The downgrade from Neutral to Sell by a major financial institution like Citigroup is likely to negatively impact investor sentiment and could lead to a decrease in CRL's stock price. The lowered price target from $215 to $175 suggests that Citigroup expects the stock to underperform.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100